1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Antibody Drug Conjugates Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Antibody Drug Conjugates Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Antibody Drug Conjugates Market Regional Analysis
6.2 North America Antibody Drug Conjugates Market Revenue 2020-2030 (US$ Million)
6.3 North America Antibody Drug Conjugates Market Forecast Analysis
7. North America Antibody Drug Conjugates Market Analysis – by Technology
7.1 Cleavable Linker
- 7.1.1 Overview
- 7.1.2 Cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Non-cleavable Linker
- 7.2.1 Overview
- 7.2.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. North America Antibody Drug Conjugates Market Analysis – by Application
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Breast Cancer
- 8.2.1 Overview
- 8.2.2 Breast Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.3 Ovarian Cancer
- 8.3.1 Overview
- 8.3.2 Ovarian Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.4 Urothelial Cancer
- 8.4.1 Overview
- 8.4.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. North America Antibody Drug Conjugates Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies : North America Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
10. North America Antibody Drug Conjugates Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Antibody Drug Conjugates Market Breakdown, by Key
Country, 2023 and 2030 (%)
- 10.2.1.1 North America Antibody Drug Conjugates Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.1.1 US: North America Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.1.2 US: North America Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.1.3 US: North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada:
North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.2.1 Canada: North America Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.2.2 Canada: North America Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.2.3 Canada: North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico :
North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.3.1 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.3.2 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.3.3 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 ADC Therapeutics SA
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Hoffmann-La Roche Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 ImmunoGen Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GSK Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Gilead Sciences Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AstraZeneca Plc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Astellas Pharma Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 RemeGen Co Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Takeda Pharmaceutical Co Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Antibody Drug Conjugates Market
